6-trifluoromethyl-2-(methylthio)benzothiazole | 401567-23-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 6-trifluoromethyl-2-(methylthio)benzothiazole
• 英文别名: Benzothiazole, 2-(methylthio)-6-(trifluoromethyl)-；2-methylsulfanyl-6-(trifluoromethyl)-1,3-benzothiazole
• CAS: 401567-23-5
• 化学式: C₉H₆F₃NS₂
• 分子量: 249.281
• InChiKey: WOSLKWIZHZGPAA-UHFFFAOYSA-N

物化性质

• 熔点：
  55.8-57.0 °C
• 沸点：
  308.7±52.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-trifluoromethyl-2-(methylthio)benzothiazole 在 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 氯仿 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 14.5h， 生成 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[6-[2-[(Z)-[(5E)-3-ethyl-5-[3-methyl-6-(trifluoromethyl)-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl]pyridin-1-ium-1-yl]hexyl]pentanamide;chloride
  参考文献：
  名称：

  Analogues of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, As Anti-Cancer Agents

  摘要：

  The rhodacyanine, MKT-077, has antiproliferative activity against cancer cell lines through its ability to inhibit members of the heat shock protein 70 (Hsp70) family of molecular chaperones. However, MKT-077 is rapidly metabolized, which limits its use as either a chemical probe or potential therapeutic. We report the synthesis and characterization of MKT-077 analogues designed for greater stability. The most potent molecules, such as 30 (JG-98), were at least 3-fold more active than MKT-077 against the breast cancer cell lines MDA-MB-231 and MCF-7 (EC50 values of 0.4 +/- 0.03 and 0.7 +/- 0.2 mu M, respectively). The analogues modestly destabilized the chaperone clients, Aka and Raf1, and induced apoptosis in these cells. Further, the microsomal half-life of JG-98 was improved at least 7-fold (t(1/2) = 37 min) compared to MKT-077 (t(1/2) < 5 min). Finally, NMR titration experiments suggested that these analogues bind an allosteric site that is known to accommodate MKT-077. These studies advance MKT-077 analogues as chemical probes for studying Hsp70s roles in cancer.

  DOI：

  10.1021/ml400204n
• 作为产物：
  描述：

  3-氯-4-氨基三氟甲苯 在 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 6-trifluoromethyl-2-(methylthio)benzothiazole
  参考文献：
  名称：

  Analogues of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, As Anti-Cancer Agents

  摘要：

  The rhodacyanine, MKT-077, has antiproliferative activity against cancer cell lines through its ability to inhibit members of the heat shock protein 70 (Hsp70) family of molecular chaperones. However, MKT-077 is rapidly metabolized, which limits its use as either a chemical probe or potential therapeutic. We report the synthesis and characterization of MKT-077 analogues designed for greater stability. The most potent molecules, such as 30 (JG-98), were at least 3-fold more active than MKT-077 against the breast cancer cell lines MDA-MB-231 and MCF-7 (EC50 values of 0.4 +/- 0.03 and 0.7 +/- 0.2 mu M, respectively). The analogues modestly destabilized the chaperone clients, Aka and Raf1, and induced apoptosis in these cells. Further, the microsomal half-life of JG-98 was improved at least 7-fold (t(1/2) = 37 min) compared to MKT-077 (t(1/2) < 5 min). Finally, NMR titration experiments suggested that these analogues bind an allosteric site that is known to accommodate MKT-077. These studies advance MKT-077 analogues as chemical probes for studying Hsp70s roles in cancer.

  DOI：

  10.1021/ml400204n

文献信息

• Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein–Protein Interactions with Heat Shock Protein 70 (Hsp70)
  作者：Hao Shao、Xiaokai Li、Michael A. Moses、Luke A. Gilbert、Chakrapani Kalyanaraman、Zapporah T. Young、Margarita Chernova、Sara N. Journey、Jonathan S. Weissman、Byron Hann、Matthew P. Jacobson、Len Neckers、Jason E. Gestwicki

  DOI：10.1021/acs.jmedchem.8b00583

  日期：2018.7.26

  Cancer cells rely on the chaperone heat shock protein 70 (Hsp70) for survival and proliferation. Recently, benzothiazole rhodacyanines have been shown to bind an allosteric site on Hsp70, interrupting its binding to nucleotide-exchange factors (NEFs) and promoting cell death in breast cancer cell lines. However, proof-of-concept molecules, such as JG-98, have relatively modest potency (EC50 ≈ 0.7–0

  癌细胞依靠伴侣热休克蛋白 70 (Hsp70) 来生存和增殖。最近，苯并噻唑罗丹青素已被证明与 Hsp70 上的变构位点结合，中断其与核苷酸交换因子 (NEF) 的结合并促进乳腺癌细胞系中的细胞死亡。然而，概念验证分子，如 JG-98，具有相对适中的效力（EC 50 ≈ 0.7–0.4 μM），并且在动物中迅速代谢。在这里，我们通过~300 种类似物的基于结构和特性的设计探索了这个化学系列，表明最有效的 EC 50提高了 10 倍以上值（~0.05 至 0.03 μM）对抗两种乳腺癌细胞。生物标志物和全基因组 CRISPRi 筛选证实 Hsp70 家族的成员是细胞靶点。基于这些结果，发现 JG-231 可减少 MDA-MB-231 异种移植模型（4 mg/kg，腹腔注射）中的肿瘤负荷。总之，这些研究支持 Hsp70 可能是抗癌治疗的有希望的靶点的假设。
• Proline derivatives and use thereof as drugs
  申请人：Kitajima Hiroshi

  公开号：US20050245538A1

  公开（公告）日：2005-11-03

  The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the γ-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

  本发明旨在提供具有治疗效果的化合物，其作用是通过DPP-IV的抑制作用，并且作为药物产品具有令人满意的效果。本发明人发现，在丙氨酸的γ位上引入取代基的衍生物具有强效的DPP-IV抑制活性，并通过增加稳定性完成了本发明。
• Proline derivatives and the use thereof as drugs
  申请人：——

  公开号：US20040106655A1

  公开（公告）日：2004-06-03

  The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the &ggr;-position of proline represented by the formula (I) 1 wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

  本发明旨在提供具有治疗作用的化合物，由于DPP-IV抑制作用而具有满意的药物产品。本发明人发现，具有引入取代基的脯氨酸γ-位置的衍生物，其化学式为(I)1，其中每个符号如规范中所定义，具有强效的DPP-IV抑制活性，并通过增加稳定性完成了本发明。
• PROLINE DERIVATIVES AND USE THEREOF AS DRUGS
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1308439B1

  公开（公告）日：2008-10-15
• Novel KCNQ2/Q3 Agonists as Potential Therapeutics for Epilepsy and Neuropathic Pain
  作者：Paul C. Fritch、Grant McNaughton-Smith、George S. Amato、James F. Burns、C. Wesley Eargle、Rosemarie Roeloffs、William Harrison、Leslie Jones、Alan D. Wickenden

  DOI：10.1021/jm901497b

  日期：2010.1.28

  Current drugs for the treatment of seizure disorders, although effective in many patients, still suffer from a number of failures and are not effective in some forms of resistant epilepsies. Historically, many of these drugs have multiple mechanisms of action including calcium and sodium channel blockade as well as GABAergic activity and thus a number of associated side effects. Modulation of the M-current through opening of KCNQ channels has been proposed as a way to attenuate neuroexcitability and have a therapeutic benefit for the treatment Of seizure disorders. Therefore, as part Of our program to identify new treatments for epilepsy, we set out to identify agonists of KCNQ channels. High throughput screening of our corporate collection led to the identification of 1, adamantane-1-carboxylic acid (3-methyl-3H-benzothiazol-2-ylidine) hydrazide, a potent KCNQ2/Q3 agonist. Herein, we describe the syntheses and structure-activity relationships of analogues of I its well as their in vivo activity in animal models of epilepsy and neuropathic pain.